Has the Introduction of PARPi Changed Healthcare Resource Utilization (HCRU) and Medical Costs Among Patients With High-Grade Serous Ovarian Cancer (HGSOC) in the Real-Life Setting in Finland?

Speaker(s)

Mascialino B1, Lahelma M2, Salo K2, Heikkilä E2, Herse F2, Idänpään-Heikkilä J3, Käkelä S3, Tikka S3, Schneider D4, Hietanen S5, Loukovaara M6, Auranen A7
1GSK, Verona, Italy, 2Nordic Healthcare Group, Helsinki, Finland, 3GSK, Espoo, Finland, 4GSK, Baar Onyx, Switzerland, 5Turku University Hospital, Turku, Finland, 6Helsinki University Hospital, Helsinki, Finland, 7Tays Cancer Centre, Tampere University Hospital and Tampere University, Tampere, Finland

Presentation Documents

OBJECTIVES: This multicenter, retrospective, non-interventional study collected medical records from Helsinki, Turku and Tampere University Hospitals on patients with HGSOC. Previous data show that mean HCRU cost during the first year after diagnosis was highest for patients with Stage III–IV HGSOC with visible residual disease (€23,700). New results from this study summarize recent HCRU from all three regions. This abstract describes results from Helsinki University Hospital.

METHODS: Patients with newly diagnosed HGSOC who received treatment in Helsinki University Hospital during 2019–2023 were included, covering ~30% of the Finnish HGSOC population. HCRU and medical costs for the first year following diagnosis were retrospectively collected.

RESULTS: Of the 422 patients with HGSOC identified (mean age 69 years), 337 had known tumor staging: 11% (n=47) were Stage I–II, 26% (n=109) were Stage III and 43% (n=181) were Stage IV. Patients received either poly-ADP ribose polymerase inhibitor (PARPi) monotherapy (4%, n=18), PARPi plus bevacizumab (13%, n=53), bevacizumab monotherapy (35%, n=148) or active surveillance (48%, n=203) as maintenance treatment. Most (73%, n=308) patients in the study were BRCAwt (11% BRCAmut; 16% unknown). Of those, 34 received niraparib monotherapy in any treatment line. During the first year after HGSOC diagnosis, patients receiving PARPi monotherapy had the lowest average outpatient visits (10.0), while patients receiving PARPi plus bevacizumab had the highest (18.1). Patients receiving bevacizumab monotherapy had the highest average emergency care visits (2.5) and inpatient admissions (1.3), while patients on PARPi monotherapy had the lowest (1.2 and 1.1, respectively). The average cost per patient during the first year after HGSOC diagnosis was €20,765 for patients receiving PARPi monotherapy, €25,225 for bevacizumab monotherapy, €24,205 for PARPi plus bevacizumab and €21,297 for BRCAwt patients receiving niraparib monotherapy.

CONCLUSIONS: HCRU and costs remain high for patients with HGSOC. Those receiving PARPi monotherapy may have lower medical costs.

Code

EE196

Topic

Economic Evaluation

Disease

Oncology, Reproductive & Sexual Health